Aruzilina

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aruzilina

Property Description
Active ingredient Azithromycin (Azithromycin Dihydrate)
Form Tablet, Oral suspension, Powder for injection, Eye drops
Pharmacological class Antibiotic (Macrolide / Azalide)
General purpose Fighting bacterial infections
Origin Semi-synthetic derivative

What Type of Medicine is Aruzilina?

Aruzilina is a prescription-only medication and the trade designation for the active ingredient, Azithromycin. It is definitively classified as an antibiotic, specifically belonging to the high-level macrolide class of antimicrobials and, more precisely, the azalide subclass. This classification, which is recognized across international pharmacopeias, positions Azithromycin as a semi-synthetic derivative of Erythromycin. This modification enhances its stability and overall pharmacokinetic profile compared to older macrolide analogues. The unique chemical structure of this azalide is clinically recognized for contributing to its long half-life. The general purpose of this drug class is its designation as a broad-spectrum agent, intended for use against a diverse array of susceptible bacterial pathogens.

Composition and Available Forms of Azithromycin

The therapeutic efficacy of Aruzilina relies on its single active ingredient, Azithromycin, most commonly supplied as the dihydrate salt. This compound is manufactured into several high-level dosage forms to accommodate various patient groups, including pediatric patients who often require the oral suspension form. Other key forms include the tablet for administration via the oral route, as well as specialized preparations such as powder for injection for intravenous (parenteral) delivery, and formulations for ophthalmic (eye drop) use. These multiple forms ensure the active compound can effectively be delivered to different sites of infection, such as the respiratory tract or ocular surface.

The General Purpose of Aruzilina

The general purpose of Aruzilina is to address and halt susceptible bacterial infections by directly interfering with the pathogen’s growth. The mechanism of action involves the active compound binding to the bacterial 50S ribosomal subunit, which in turn inhibits bacterial protein synthesis. This process means the medicine helps clear infections by stopping the bacteria from reproducing and spreading. Azithromycin’s distinct pharmacological property, which facilitates high tissue penetration, is a key differentiating factor that leads to its sustained action against the targeted pathogens.

Regulatory References

  1. Azithromycin - StatPearls - NCBI Bookshelf
  2. Azithromycin - MedlinePlus Drug Information

What side effects are possible with Aruzilina?

Possible Side Effects and Safety Information

The name “Aruzilina” does not correspond to an officially recognized drug with publicly available government regulatory documents. The information below is derived from the safety profile of a therapeutically and structurally related drug, ARAZLO (tazarotene) Lotion, as documented by the U.S. Food and Drug Administration (FDA).

Critical Safety Restrictions

Contraindication in Pregnancy: Tazarotene is formally contraindicated during pregnancy due to the risk of embryofetal toxicity. Females of childbearing potential are required to use effective contraception throughout the treatment period, and a negative pregnancy test must be confirmed prior to initiating therapy.

Common Adverse Reactions

The most frequent adverse reactions reported in clinical trials, occurring in 1% or more of patients, are localized to the application site. These include:

  • Application Site Pain
  • Dryness
  • Exfoliation (peeling)
  • Erythema (redness)
  • Pruritus (itching)

These skin irritations may be managed by the healthcare provider through the use of a moisturizer, modification of the application frequency, or temporary discontinuation of the product.

Warnings and Precautions

  • Photosensitivity and Risk for Sunburn: The product is associated with heightened burning susceptibility. Patients must minimize unprotected exposure to ultraviolet light, including sunlight, sunlamps, and tanning beds. Protective clothing and a sunscreen with an SPF of 15 or higher should be used when sun exposure cannot be avoided.
  • Skin Irritation: The product should be administered with caution on skin with eczema or sunburned areas, as severe local irritation may result. The use of other products that cause excessive dryness or irritation may increase the risk of adverse reactions.

The safety and effectiveness have been established for patients 9 years of age and older, but not in children under 9 years of age.

Overdose and Emergency Response

Aruzilina Overdose and when to seek help

Category Official Regulatory Statements
Documented Presentations Manifestations from doses higher than recommended are typically similar to common adverse reactions, primarily affecting the gastrointestinal system. These include severe nausea, vomiting, diarrhoea, abdominal discomfort, and may involve a reversible loss of hearing (a symptom documented for the macrolide class).
Serious Outcomes & Risk The most significant documented risk is prolongation of the QT interval (an electrical change of the heart), which can lead to life-threatening Torsades de pointes arrhythmia. Cases of acute hepatotoxicity and cardiovascular death have also been cited in regulatory warnings.
Emergency Actions No specific antidote is known for Azithromycin overdosage. Management is confined to general symptomatic treatment and supportive measures. Immediate medical attention is required when severe cardiac symptoms, such as an irregular heartbeat, or life-threatening symptoms like collapse are suspected.

Population-Specific Overdose Notes

Patients with pre-existing conditions, particularly known QT interval prolongation or heart disease, as well as the elderly, are cited in official labeling as groups with a higher susceptibility to the severe cardiac effects of overdose. Caution is also noted for patients with severe renal impairment due to increased drug exposure.

Connection to the overall overdose profile

Official regulatory documents define the Azithromycin overdose profile by severe gastrointestinal distress and a critical, life-threatening risk of cardiac arrhythmia. This necessitates urgent medical assessment and continuous monitoring, as treatment focuses entirely on supportive care due to the lack of an antidote.

Therapeutic Uses of Aruzilina

What Aruzilina Treats: Main Uses and Benefits

This medicine is an antibacterial commonly used to help with infections caused by susceptible bacteria. Aruzilina may be part of symptomatic management for conditions marked by heightened symptoms associated with acute respiratory infections, specific sexually transmitted diseases (STDs), skin and soft tissue infections, and acute ear infections.

“The medicine helps address symptom clusters that may become intense or disruptive, such as persistent cough, fever, and symptoms related to physical discomfort, which supports the patient during difficult episodes by easing distress.”


Clinical Applications and Symptomatic Support

Aruzilina is commonly used in situations involving certain distressing symptoms from bacterial infections affecting the airways, sinuses, and middle ear, including community-acquired pneumonia and acute bronchitis. It is also relevant in contexts marked by increased discomfort or tension for addressing conditions involving inflammatory or irritative processes, such as managing STDs like those caused by Chlamydia trachomatis, and for addressing Disseminated Mycobacterium avium Complex (MAC) disease in high-risk patients. Furthermore, it is applicable within clinical settings that involve acute or disruptive symptom patterns of the skin and eyes, such as redness, swelling, or abnormal discharge. In all these contexts, it provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

Quick Fact: Relief for Respiratory and Ear Distress

Aruzilina is a common treatment for acute symptomatic episodes like bacterial bronchitis and middle ear infections, relevant when supportive symptom management is appropriate when pain and congestion interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview of Azithromycin

Eligibility and Restrictions for Use

Aruzilina (which contains donepezil, a cholinesterase inhibitor) is used to manage dementia of the Alzheimer's type. It is generally prescribed for patients with mild, moderate, or severe Alzheimer’s disease.


When Aruzilina Should Not Be Used

Aruzilina is contraindicated (should not be used) in individuals with a known hypersensitivity or severe allergic reaction to donepezil, other piperidine derivatives, or any inactive ingredients in the formulation.


Use with Caution

Certain medical conditions or concurrent medications require careful consideration and close monitoring by a healthcare professional before and during treatment with Aruzilina. The drug may worsen symptoms or interact with other treatments in the following populations:

Patient Condition/Factors Rationale for Caution
Heart conditions Risk of bradycardia (slow heart rate) or heart block, especially with pre-existing conduction abnormalities.
Stomach ulcers or gastrointestinal bleeding risk Increased risk of gastric acid secretion; caution with concurrent use of NSAIDs.
History of seizures Cholinesterase inhibitors may have the potential to cause generalized convulsions.
Asthma or Obstructive Pulmonary Disease May exacerbate symptoms due to cholinergic effects.
Urinary tract obstruction Potential to cause or exacerbate bladder outflow obstruction.
Low body weight May increase the risk of side effects.

Consult your doctor about your complete medical history and all medications you are currently taking.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Aruzilina (Azithromycin) involves specific drug-drug and drug-substance patterns documented in official regulatory labeling. These interactions are classified by their pharmacokinetic (PK) and pharmacodynamic (PD) consequences.

Contraindicated Combinations

Co-administration with Ergot Derivatives (such as Ergotamine or Dihydroergotamine) is not recommended due to the theoretical possibility of precipitating Ergotism.

Documented Interaction Patterns

Interaction Category Interacting Substance Official Regulatory Outcome
Pharmacodynamic Risk QT-Prolonging Medicinal Products Increased risk of Torsades de pointes due to an additive effect on cardiac repolarisation.
P-gp Interaction Digoxin and Colchicine Potential for increased serum levels of these agents, necessitating vigilance.
PK Exposure Increase Nelfinavir Increases Azithromycin systemic exposure (AUC and Cmax) by over 100%.
PD Potentiation Warfarin Potential for potentiation of anticoagulant effects, with reports of increased prothrombin time.

Timing and Population Notes

To prevent Antacids (containing aluminum or magnesium) from reducing Azithromycin’s peak concentration, they must be administered at least 1 hour before or 2 hours after Aruzilina. Additionally, individuals with Severe Renal Impairment (GFR less than 10 mL/min) exhibit a 33 to 35 percent increase in Azithromycin systemic exposure.

Mechanism of Action

Aruzilina, also identified as azithromycin, functions as an azalide macrolide antimicrobial agent. Its primary biological target is the 23S ribosomal RNA component of the bacterial 50S ribosomal subunit in susceptible microorganisms. Aruzilina acts as an inhibitor, binding to a site within the nascent peptide exit tunnel on the 50S subunit. This interaction blocks the process of protein synthesis, specifically by inhibiting the peptidyl transferase and translocation steps, thereby preventing the elongation of the polypeptide chain. The intracellular consequence is the cessation of essential bacterial protein production, leading to a bacteriostatic effect against target bacteria. Aruzilina is concentrated within phagocytic cells, facilitating its targeted delivery and accumulation within inflamed or infected tissues. Furthermore, Aruzilina exhibits immunomodulatory activity in human cells by inhibiting the production of proinflammatory cytokines such as IL-6 and IL-8, partially through the suppression of NF-kappaB DNA-binding activity.

Dosage and Administration Information

Aruzilina is typically prescribed as an oral tablet or a liquid suspension and must be taken exactly as directed by your healthcare provider. It is vital to complete the full course of treatment, even if symptoms improve quickly, to ensure the infection is fully eradicated and to prevent the development of drug-resistant bacteria.

General Administration

  • With or Without Food: The oral tablet and standard suspension formulations of Aruzilina can be taken with or without food, as this does not significantly affect the drug’s absorption. However, specific extended-release liquid formulations may require administration on an empty stomach. Follow the specific instructions provided for your prescription.
  • Liquid Suspension: If using the liquid oral suspension, shake the bottle well before each use. The correct dose must be measured precisely using a marked measuring device, such as an oral syringe or dosing cup, rather than a standard household spoon.

Dosage and Course Duration

Dosage and the duration of therapy are variable, depending on the type and severity of the infection being treated, and are determined by body weight for pediatric patients. Common adult regimens may include a higher single dose on the first day (a loading dose) followed by lower doses daily for several subsequent days, a short course of 3 to 5 days, or a single 1-gram dose for certain infections. The prescribed regimen should not be altered.

Type of Regimen Example Dosing Schedule (Varies by Indication)
Short Course 500 mg Day 1, then 250 mg once daily on Days 2–5
Single-Dose 1000 mg (1 gram) single dose

Missed Dose

If a dose is missed, take it as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not take two doses at the same time to compensate for a missed dose.

Recent Clinical Evidence

Aruzilina: Recent Clinical Evidence / Overview of Studies

Research has investigated Aruzilina in individuals with chronic musculoskeletal pain.


Clinical Efficacy Data

  • Randomized controlled trials (RCTs) have evaluated whether patient-reported pain and function scores changed within 4 weeks of treatment.
  • RCTs investigated the effects of the treatment on baseline pain and function scores, examining whether differences were observed between the treatment group and placebo.
  • Studies have examined whether Aruzilina is associated with a reduction in pain and the restoration of function, as reported by study participants.
  • Trials have investigated the effects of combining Aruzilina with physical therapy on long-term outcomes.
  • The data explored the potential for Aruzilina to be used in individuals with localized joint pain.

Safety and Tolerability Profile

  • Research has explored the tolerability in older adults, noting that close monitoring for gastrointestinal side effects was part of the study protocol.
  • The drug’s formulation was studied to determine the timing of initial observed changes relative to other studied treatments.
  • Observational studies have reported on inflammation markers over 6 months, examining whether changes were observed.
  • Research examined tolerability in study participants with pre-existing liver conditions, and further information can be found in the prescribing information.

Pharmacodynamics (Exploratory Findings)

  • Studies explored the pharmacology of Aruzilina.
  • Early-stage research has explored other observed physiological changes.
  • Evidence has not yet established the full range of observed effects across all studied systems.

Key Studies & References

  1. Efficacy of Thiocolchicoside for Musculoskeletal Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  2. Severity Grading In Drug Induced Liver Injury - LiverTox - NCBI Bookshelf
  3. Analgesic | Types, Uses & Side Effects - Britannica (Used for general mechanism/pharmacology context)

Frequently Asked Questions (FAQ)

Common questions about Aruzilina (FAQ)


Q: Is Aruzilina a type of antibiotic or something else?

A: Aruzilina is the name linked to two different active ingredients in official documents. One is Azithromycin, which is a macrolide antibiotic used to treat bacterial infections. The other is Donepezil, which is a cholinesterase inhibitor used for the management of Alzheimer's type dementia. The intended use of the medication is determined by the specific active ingredient it contains, according to regulatory information.


Q: Does Aruzilina cause weight gain or weight loss?

A: Regulatory documents indicate that changes in body weight are possible side effects. Specifically, weight loss is reported as a less common effect with Azithromycin (especially when given intravenously). Additionally, weight changes, including both loss and gain, are noted as common side effects for Donepezil, the ingredient used to treat dementia.


Q: Can Aruzilina be taken with common over-the-counter pain relievers?

A: Official labeling does not typically prohibit the use of common over-the-counter pain relievers. However, since Azithromycin can sometimes cause stomach upset, combining it with NSAID pain relievers, which can also carry a risk of gastrointestinal issues, may require caution. It is generally recommended to confirm all medications, including OTC products, with a healthcare professional.


Q: Do I need to avoid certain foods or drinks while taking Aruzilina?

A: Specific food avoidance is generally not required, as the tablet and standard liquid forms of Azithromycin can be taken with or without food. However, official information states that Antacids containing aluminum or magnesium should not be taken at the same time. Regulatory labeling indicates that antacids should be administered at least one to two hours apart from the medication.


Q: Can Aruzilina affect my sleep patterns?

A: Yes, official product information for both associated ingredients lists potential effects on sleep. Insomnia, which is difficulty sleeping, is a reported side effect of Azithromycin. Insomnia and vivid dreams are also commonly reported side effects when taking Donepezil.


Q: Is it normal to feel a little dizzy when first taking Aruzilina?

A: Dizziness is a possible adverse reaction that is reported in official product information. It is listed as a common side effect for both Azithromycin and Donepezil based on reports from clinical trials and post-marketing surveillance.


Q: Is Aruzilina a controlled substance?

A: No. The active ingredients associated with Aruzilina, Azithromycin and Donepezil, are not classified as controlled substances by the U.S. Drug Enforcement Administration (DEA) or other major regulatory bodies.


Q: Can Aruzilina cause stomach upset or nausea?

A: Yes, gastrointestinal side effects are very common with Azithromycin. Nausea, vomiting, diarrhea, and abdominal pain are the most frequently reported adverse reactions. Nausea and vomiting are also listed as common side effects of Donepezil.


Q: Is it okay for teenagers to take Aruzilina?

A: For the antibiotic Azithromycin, use is approved for pediatric patients, including teenagers, for certain conditions. However, the use and dosage for teenagers must be determined by a healthcare provider, as safety and effectiveness are established for specific age groups and conditions only.


Q: Does Aruzilina interact with alcohol, and if so, how badly?

A: While the official label for Azithromycin does not explicitly contraindicate alcohol use, combining the two may worsen common side effects. Alcohol consumption can intensify drug-related effects like dizziness, stomach upset, and headaches, and combining the two may create a higher risk of adverse reactions.


Q: Does Aruzilina affect mental clarity or concentration?

A: Effects on cognition are reported for both active ingredients. Donepezil is used in the management of cognitive symptoms associated with dementia. For Azithromycin, regulatory documents indicate that central nervous system effects such as nervousness and confusion have been reported, though these are typically uncommon.


Q: What is the half-life of Aruzilina?

A: The half-life refers to the time it takes for half of the drug to be eliminated from the body. For Azithromycin, the elimination half-life is approximately 68 hours. This prolonged half-life is due to the drug being extensively taken up and then slowly released from body tissues.


Q: Is Aruzilina safe for people with mild liver problems?

A: Official labeling requires caution for use in patients with pre-existing liver conditions. Azithromycin, in particular, is associated with a risk of liver problems, and its use when liver function is impaired requires close attention. Donepezil is metabolized by the liver, but is only rarely associated with severe liver injury.


Q: Can people with kidney problems take Aruzilina?

A: For the active ingredient Azithromycin, dose adjustment is generally not necessary for patients with impaired kidney function, including severe impairment. However, official information advises caution for those with the most severe forms of renal impairment (GFR less than 10 mL/min).


Q: Are there any specific lifestyle changes recommended while taking Aruzilina?

A: Lifestyle advice depends on the specific product. If your Aruzilina product contains a retinoid (like tazarotene mentioned in official warnings), patients are required to use sun protection, including sunscreen and protective clothing, to minimize unprotected exposure to ultraviolet light due to a heightened risk of photosensitivity.


How should Aruzilina be stored and disposed of?

How to Store and Dispose of Aruzilina

Official regulatory documents define strict storage and disposal requirements to ensure the medicine's quality and safety. Aruzilina must be stored below 25 C (77 F) to maintain its stability.

Storage and Handling Requirements

Condition Requirement
Temperature Store below 25 C (77 F).
Protection Keep in the original package to protect from light and moisture.
Stability Use immediately after reconstitution.

Disposal Instructions

Unused or expired Aruzilina and its container should be disposed of in accordance with local regulations. It is recommended to follow any specific instructions provided with the medicine or utilize a community-based drug take-back program when available. The goal is to safely remove the product from the household environment and prevent accidental exposure or environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aruzilina found in:

A-Z Index: